Pozzi C, Pasquali S, Donini U, Casanova S, Banfi G, Tiraboschi G, Furci L, Porri M T, Ravelli M, Lupo A
Clin Nephrol. 1987 Jul;28(1):1-9.
We studied 50 patients with myeloma acute renal failure to investigate possible prognostic factors and to evaluate the effectiveness of the various treatment schedules used. Renal failure was reversible 1 month after the onset in 50% of the patients considered. The patients treated with chemotherapy and plasma exchange recovered renal function more frequently (61% of the cases) than those treated only with chemotherapy (27%). The most important clinical prognostic factors were total proteins, serum creatinine values and myeloma type. Considering the histological findings, the prognosis correlated with the severity of the lesions and number of tubular casts. Survival at 1 year was higher in the patients who regained renal function than in those in whom renal function did not improve.
我们研究了50例骨髓瘤急性肾衰竭患者，以调查可能的预后因素，并评估所采用的各种治疗方案的有效性。在被评估的患者中，50%的患者肾衰竭在发病1个月后可逆。接受化疗和血浆置换治疗的患者肾功能恢复的频率（61%的病例）高于仅接受化疗的患者（27%）。最重要的临床预后因素是总蛋白、血清肌酐值和骨髓瘤类型。考虑到组织学结果，预后与病变的严重程度和肾小管管型数量相关。肾功能恢复的患者1年生存率高于肾功能未改善的患者。
